Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luciano Mutti

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Basic Research in Cardiology|September 3, 2024
Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patientsGiuseppe Panuccio, Pierpaolo Correale, Maria d'Apolito, et al.
International Journal of Cancer|February 10, 2007
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesotheliomaStefano Landi, Federica Gemignani, Monica Neri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2018
Scientific Advances and New Frontiers in Mesothelioma TherapeuticsLuciano Mutti, Tobias Peikert, Bruce W S Robinson, et al.
Mutation Research|March 17, 2015
Expression status of candidate genes in mesothelioma tissues and cell linesOmbretta Melaiu, Erika Melissari, Luciano Mutti, et al.
Cancers|March 28, 2024
Impact of Center Volume on Cardiopulmonary and Mortality Outcomes after Immune-Checkpoint Inhibitors for Cancer: A Systematic Review and Meta-AnalysisMohamed Rahouma, Nathan Mynard, Massimo Baudo, et al.
Biology Direct|April 18, 2023
Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivoMonica Benvenuto, Valentina Angiolini, Chiara Focaccetti, et al.
Mutation Research|September 16, 2009
Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolismFederica Gemignani, Monica Neri, Fabio Bottari, et al.
Genes & Cancer|April 25, 2017
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell linesOmbretta Melaiu, Calogerina Catalano, Chiara De Santi, et al.
Journal of Cellular and Molecular Medicine|April 18, 2020
PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approachMarcella Barbarino, Daniele Cesari, Maria Bottaro, et al.
Scientific Reports|June 11, 2017
Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolismChiara De Santi, Ombretta Melaiu, Alessandra Bonotti, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Basic Research in Cardiology|September 3, 2024
Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patientsGiuseppe Panuccio, Pierpaolo Correale, Maria d'Apolito, et al.
International Journal of Cancer|February 10, 2007
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesotheliomaStefano Landi, Federica Gemignani, Monica Neri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2018
Scientific Advances and New Frontiers in Mesothelioma TherapeuticsLuciano Mutti, Tobias Peikert, Bruce W S Robinson, et al.
Mutation Research|March 17, 2015
Expression status of candidate genes in mesothelioma tissues and cell linesOmbretta Melaiu, Erika Melissari, Luciano Mutti, et al.
Cancers|March 28, 2024
Impact of Center Volume on Cardiopulmonary and Mortality Outcomes after Immune-Checkpoint Inhibitors for Cancer: A Systematic Review and Meta-AnalysisMohamed Rahouma, Nathan Mynard, Massimo Baudo, et al.
Biology Direct|April 18, 2023
Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivoMonica Benvenuto, Valentina Angiolini, Chiara Focaccetti, et al.
Mutation Research|September 16, 2009
Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolismFederica Gemignani, Monica Neri, Fabio Bottari, et al.
Genes & Cancer|April 25, 2017
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell linesOmbretta Melaiu, Calogerina Catalano, Chiara De Santi, et al.
Journal of Cellular and Molecular Medicine|April 18, 2020
PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approachMarcella Barbarino, Daniele Cesari, Maria Bottaro, et al.
Scientific Reports|June 11, 2017
Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolismChiara De Santi, Ombretta Melaiu, Alessandra Bonotti, et al.
Pageof 13